Back to Search Start Over

Prognostic Value of MicroRNA-20b in Acute Myeloid Leukemia

Authors :
Zhiheng Cheng
Yifeng Dai
Wenhui Huang
Qingfu Zhong
Pei Zhu
Wenjuan Zhang
Zhihua Wu
Qing Lin
Huoyan Zhu
Longzhen Cui
Tingting Qian
Cong Deng
Lin Fu
Yan Liu
Tiansheng Zeng
Source :
Frontiers in Oncology, Vol 10 (2021)
Publication Year :
2021
Publisher :
Frontiers Media S.A., 2021.

Abstract

Acute myeloid leukemia (AML) is a highly heterogeneous disease that requires fine-grained risk stratification for the best prognosis of patients. As a class of small non-coding RNAs with important biological functions, microRNAs play a crucial role in the pathogenesis of AML. To assess the prognostic impact of miR-20b on AML in the presence of other clinical and molecular factors, we screened 90 AML patients receiving chemotherapy only and 74 also undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) from the Cancer Genome Atlas (TCGA) database. In the chemotherapy-only group, high miR-20b expression subgroup had shorter event-free survival (EFS) and overall survival (OS, both P < 0.001); whereas, there were no significant differences in EFS and OS between high and low expression subgroups in the allo-HSCT group. Then we divided all patients into high and low expression groups based on median miR-20b expression level. In the high expression group, patients treated with allo-HSCT had longer EFS and OS than those with chemotherapy alone (both P < 0.01); however, there were no significant differences in EFS and OS between different treatment subgroups in the low expression group. Further analysis showed that miR-20b was negatively correlated with genes in “ribosome,” “myeloid leukocyte mediated immunity,” and “DNA replication” signaling pathways. ORAI2, the gene with the strongest correlation with miR-20b, also had significant prognostic value in patients undergoing chemotherapy but not in the allo-HSCT group. In conclusion, our findings suggest that high miR-20b expression is a poor prognostic indicator for AML, but allo-HSCT may override its prognostic impact.

Details

Language :
English
ISSN :
2234943X
Volume :
10
Database :
Directory of Open Access Journals
Journal :
Frontiers in Oncology
Publication Type :
Academic Journal
Accession number :
edsdoj.1828becd1764bb987194712e6d252b7
Document Type :
article
Full Text :
https://doi.org/10.3389/fonc.2020.553344